Historically, Brazil lacks the production of Active Pharmaceutical Ingredients (API) which are the basis for domestic pharmaceutical production. This deficiency has been seriously affected by the pandemic and by the war in Europe. Here we present a brief history, the current status, and the impact of the lack of API on public pharmaceutical production in Brazil. Our experience in the development and innovation of APIs will be shown, trying to meet the needs of our Unified Health System (SUS).